DelveInsight’s “Cushing Syndrome Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Cushing Syndrome Pipeline? @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight

Key Takeaways from the Cushing Syndrome Pipeline Report

• On May 12, 2026, Sparrow Pharmaceuticals initiated a clinical trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol. CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben.
• DelveInsight’s Cushing Syndrome Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Cushing Syndrome treatment.
• The leading Cushing Syndrome Companies such as Stero Therapeutics, Sparrow Pharmaceuticals and others.
• Promising Cushing Syndrome Therapies such as SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, Levoketoconazole, mifepristone, CORT125134 and others.

Want to know which companies are leading innovation in Cushing Syndrome? @ Cushing Syndrome Clinical Trials Assessment

The Cushing Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Cushing Syndrome Pipeline Report also highlights the unmet needs with respect to the Cushing Syndrome.

Cushing Syndrome Overview

Cushing’s syndrome arises from prolonged exposure to elevated levels of circulating glucocorticoids, with Cushing’s disease, pituitary-dependent hypercortisolism, being the most common cause of endogenous cases. It is characterized by a wide range of symptoms, with common manifestations including decreased libido, obesity or weight gain, plethora (reddish complexion), rounded face, menstrual changes, hirsutism, hypertension, easy bruising (ecchymoses), lethargy, depression, proximal muscle weakness, and skin changes such as striae. Less common symptoms may involve EKG abnormalities or atherosclerosis, dorsal fat pad, edema, abnormal glucose tolerance, osteopenia or fractures, headaches, backaches, recurrent infections, abdominal pain, acne, and female-pattern baldness.

Cushing Syndrome Emerging Drugs

• ST-002: Stero Therapeutics

ST-002 is specifically designed to address the hyperglycemia and non-alcoholic steatohepatitis (NASH) associated with Cushing’s syndrome, offering a unique combination of glucocorticoid inhibition, anti-inflammatory, and anti-diabetic effects. Unlike other anti-glucocorticoid drugs, ST-002 suppresses glucocorticoid activity without reducing glucocorticoid levels, thereby avoiding adrenal insufficiency. Its safety profile has been established in over 120 patients using prior oral formulations, and as a new chemical entity (NCE), ST-002 demonstrates improved bioavailability and solubility compared to earlier versions. The U.S. FDA has granted it Orphan Disease Designation, and SteroTherapeutics is advancing its development in collaboration with the NIH under a Cooperative Research and Development Agreement (CRADA). Currently, the drug is in Phase II stage of its clinical trial for Cushing Syndrome.

If you’re tracking ongoing Cushing Syndrome Clinical trials, this press release is a must-read @ Cushing Syndrome Treatment Drugs

The Cushing Syndrome Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Cushing Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cushing Syndrome Treatment.
• Cushing Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cushing Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cushing Syndrome market.

Cushing Syndrome Companies

Stero Therapeutics, Sparrow Pharmaceuticals and others.

Cushing Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Cushing Syndrome Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Cushing Syndrome Pipeline Report covers it all @ Cushing Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Cushing Syndrome Pipeline Report

• Coverage- Global
• Cushing Syndrome Companies- Stero Therapeutics, Sparrow Pharmaceuticals and others.
• Cushing Syndrome Therapies- SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, Levoketoconazole, mifepristone, CORT125134 and others.
• Cushing Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cushing Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Cushing Syndrome Treatment landscape in this detailed analysis @ Cushing Syndrome Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Cushing Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cushing Syndrome– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ST-002: Stero Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cushing Syndrome Key Companies
21. Cushing Syndrome Key Products
22. Cushing Syndrome- Unmet Needs
23. Cushing Syndrome- Market Drivers and Barriers
24. Cushing Syndrome- Future Perspectives and Conclusion
25. Cushing Syndrome Analyst Views
26. Cushing Syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight